News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-15 pm EDT			5-day change	1st Jan Change
6.280 ^USD	-1.72%		0.00%	-28.80%

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

All News

Mentions Relevance

May. 07	Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences	PR
May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda: Q1 Earnings Snapshot	AQ
May. 06	Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results	PR
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI
May. 06	Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 04	Vanda Pharmaceuticals Launches Motion Sickness Drug Nereus in US	MT
May. 04	Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years	RE
May. 04	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years	PR
May. 01	Vanda Pharmaceuticals US availability of Nereus for people with motion sickness	RE
May. 01	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years	PR
May. 01	Vanda Pharmaceuticals Inc. Announces Commercial Availability of Nereus (Tradipitant) for Motion Sickness Prevention in the United States	CI
Apr. 29	Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026	PR
Apr. 28	Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence	PR
Apr. 22	Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors	PR
Apr. 22	Vanda Pharmaceuticals Inc. Appoints Charles Duncan to Its Board of Directors, Effective April 22, 2026	CI
Apr. 09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
Apr. 09	Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines	PR
Apr. 08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT
Apr. 08	Vanda Pharmaceuticals announces initiation of the Thetis study, a clinical trial of Nereus(TM) for the prevention of vomiting induced by GLP-1 receptor agonists	RE
Apr. 08	Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	PR
Apr. 08	Vanda Pharmaceuticals Inc. Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS? for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	CI
Apr. 02	Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026	CI
Mar. 30	FDA Issues Final Decision on Vanda Pharmaceuticals? Hearing Request for Tradipitant NDA	CI
Mar. 22	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index	CI